.png)
ORLANDO, Fla. — The interleukin (IL)-4 and IL-13 inhibitor dupilumab improved itch symptoms and curtailed disease activity while also reducing oral corticosteroid use in older patients with bullous pemphigoid (BP), a phase 2/3 study demonstrated. “Dupilumab demonstrated significant benefits across multiple disease aspects in BP at 36 weeks...
55W 14th St Ste 101, Helena, Montana, 59601, US
+1(406)-319-1601
news.in.usa@olahost.top
Copyright © 2024 olascience. All Rights Reserved
